Freeline Therapeutics Holdings plc Key Executives
This section highlights Freeline Therapeutics Holdings plc's key executives, including their titles and compensation details.
Find Contacts at Freeline Therapeutics Holdings plc
(Showing 0 of )
Freeline Therapeutics Holdings plc Earnings
This section highlights Freeline Therapeutics Holdings plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2023 | 2023-08-15 | $-3.62 | $-0.21 |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
$6.49
Stock Price
$28.28M
Market Cap
65
Employees
Stevenage, None
Location
Financial Statements
Access annual & quarterly financial statements for Freeline Therapeutics Holdings plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $1.74M | $2.39M | $1.93M | $1.55M | $- |
| Gross Profit | $-1.74M | $-2.39M | $-1.93M | $-1.55M | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $66.20M | $95.43M | $76.15M | $47.04M | $34.19M |
| General and Administrative Expenses | $30.66M | $44.57M | $26.30M | $16.60M | $6.79M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $30.66M | $44.57M | $26.30M | $16.60M | $6.79M |
| Other Expenses | $-1.57M | $-2.09M | $-15.27M | $-10.60M | $-390.00K |
| Operating Expenses | $95.29M | $137.91M | $87.18M | $53.05M | $32.72M |
| Cost and Expenses | $95.29M | $137.91M | $87.18M | $53.05M | $32.72M |
| Interest Income | $904.00K | $403.95K | $275.00K | $74.31K | $- |
| Interest Expense | $- | $- | $- | $- | $151.00K |
| Depreciation and Amortization | $1.27M | $9.24M | $17.18M | $12.13M | $970.00K |
| EBITDA | $-97.17M | $-133.14M | $-85.27M | $-51.51M | $-32.13M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-98.45M | $-142.38M | $-102.45M | $-63.64M | $-40.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $9.84M | $2.33M | $6.26M | $9.88M | $-470.80K |
| Income Before Tax | $-88.60M | $-140.05M | $-96.19M | $-53.77M | $-33.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $368.00K | $342.00K | $129.00K | $141.00K | $27.00K |
| Net Income | $-88.97M | $-140.39M | $-96.32M | $-53.91M | $-33.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-22.52 | $-58.98 | $-102.09 | $-127.39 | $-78.65 |
| EPS Diluted | $-22.52 | $-58.98 | $-102.09 | $-127.39 | $-78.65 |
| Weighted Average Shares Outstanding | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
| Weighted Average Shares Outstanding Diluted | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | June 30, 2019 | March 31, 2019 | June 30, 2018 | March 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.00K | $617.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $383.76K | $434.39K | $322.90K | $317.36K | $402.54K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $-378.76K | $182.61K | $-322.90K | $-317.36K | $-402.54K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | -7575.20% | 29.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $5.79M | $8.83M | $10.89M | $12.64M | $14.78M | $18.84M | $19.95M | $24.60M | $22.70M | $24.27M | $23.86M | $20.88M | $25.82M | $11.99M | $17.46M | $11.76M | $11.76M | $8.55M | $8.55M |
| General and Administrative Expenses | $6.40M | $9.50M | $8.05M | $5.64M | $8.73M | $8.05M | $8.22M | $7.35M | $12.60M | $14.54M | $10.08M | $11.38M | $3.26M | $7.93M | $3.73M | $4.15M | $4.15M | $1.70M | $1.70M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $6.40M | $9.50M | $8.05M | $5.64M | $8.73M | $8.05M | $8.22M | $7.35M | $12.60M | $14.54M | $10.08M | $11.38M | $3.26M | $7.93M | $3.73M | $4.15M | $4.15M | $1.70M | $1.70M |
| Other Expenses | $-34.00K | $-591.00K | $-261.00K | $-267.00K | $-583.00K | $-335.00K | $-386.00K | $-658.00K | $3.86M | $-1.63M | $-1.73M | $-10.04M | $-114.00K | $-1.00K | $863.00K | $-31.82M | $-31.82M | $-20.49M | $-20.49M |
| Operating Expenses | $12.03M | $18.12M | $18.68M | $18.02M | $22.93M | $26.56M | $27.79M | $31.40M | $34.81M | $38.35M | $33.34M | $28.12M | $24.85M | $16.73M | $17.49M | $-15.91M | $-15.91M | $-10.25M | $-10.25M |
| Cost and Expenses | $12.03M | $18.12M | $18.68M | $18.02M | $22.93M | $26.56M | $27.79M | $31.40M | $34.81M | $38.35M | $33.34M | $28.12M | $24.85M | $16.73M | $17.49M | $15.91M | $15.91M | $10.25M | $10.25M |
| Interest Income | $98.00K | $34.00K | $206.00K | $273.00K | $296.00K | $251.00K | $84.00K | $- | $85.00K | $125.00K | $140.00K | $131.00K | $- | $- | $53.00K | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $6.39M | $296.00K | $251.00K | $- | $- | $85.00K | $- | $- | $- | $56.00K | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $386.00K | $433.00K | $-17.42M | $3.85M | $988.00K | $814.00K | $927.00K | $611.00K | $588.00K | $618.00K | $573.00K | $585.00K | $466.00K | $367.00K | $495.00K | $385.00K | $385.00K | $242.50K | $242.50K |
| EBITDA | $-11.56M | $-19.12M | $-37.51M | $-16.03M | $-22.52M | $-26.08M | $-27.24M | $-30.79M | $-34.22M | $-37.74M | $-32.77M | $-27.53M | $-24.38M | $-16.36M | $-16.99M | $-13.06M | $-13.06M | $-8.07M | $-8.07M |
| EBITDA Ratio | -231180.00% | -3099.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-12.27M | $-15.65M | $-20.08M | $-19.88M | $-23.51M | $-26.89M | $-28.17M | $-34.33M | $-35.30M | $-38.81M | $-33.94M | $-32.26M | $-29.08M | $-19.92M | $-21.19M | $-15.91M | $-15.91M | $-10.25M | $-10.25M |
| Operating Income Ratio | -245320.00% | -2536.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $134.81K | $1.79M | $21.41M | $-4.30M | $8.66M | $2.33M | $1.46M | $-54.00K | $4.09M | $-1.43M | $-995.00K | $-5.76M | $4.17M | $3.23M | $4.62M | $2.47M | $2.47M | $1.93M | $1.93M |
| Income Before Tax | $-12.05M | $-16.00M | $1.33M | $-22.73M | $-14.84M | $-24.32M | $-26.71M | $-34.39M | $-30.86M | $-39.86M | $-34.94M | $-38.02M | $-24.91M | $-16.69M | $-16.57M | $-13.44M | $-13.44M | $-8.31M | $-8.31M |
| Income Before Tax Ratio | -240940.00% | -2594.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $41.00K | $6.00K | $162.00K | $272.00K | $50.00K | $24.00K | $22.00K | $313.00K | $13.00K | $7.00K | $9.00K | $55.00K | $74.00K | $-131.00K | $131.00K | $35.25K | $35.25K | $6.75K | $6.75K |
| Net Income | $-12.09M | $-16.01M | $1.17M | $-23.00M | $-14.89M | $-24.35M | $-26.73M | $-34.70M | $-30.88M | $-39.87M | $-34.95M | $-38.08M | $-24.98M | $-16.56M | $-16.70M | $-13.48M | $-13.48M | $-8.32M | $-8.32M |
| Net Income Ratio | -241760.00% | -2594.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-2.77 | $-3.69 | $0.30 | $-5.31 | $-3.44 | $-5.66 | $-9.40 | $-14.56 | $-12.96 | $-16.76 | $-14.70 | $-15.93 | $-10.78 | $-7.24 | $-39.47 | $-0.63 | $-0.63 | $-0.39 | $-0.39 |
| EPS Diluted | $-2.77 | $-3.69 | $0.30 | $-5.31 | $-3.44 | $-5.66 | $-9.40 | $-14.56 | $-12.96 | $-16.76 | $-14.70 | $-15.93 | $-10.78 | $-7.24 | $-39.47 | $-0.63 | $-0.63 | $-0.39 | $-0.39 |
| Weighted Average Shares Outstanding | 4.36M | 4.34M | 4.34M | 4.33M | 4.33M | 4.30M | 2.84M | 2.38M | 2.38M | 2.38M | 2.38M | 2.39M | 2.32M | 2.29M | 423.19K | 21.35M | 21.35M | 21.35M | 21.35M |
| Weighted Average Shares Outstanding Diluted | 4.36M | 4.34M | 4.34M | 4.33M | 4.33M | 4.30M | 2.84M | 2.38M | 2.38M | 2.38M | 2.38M | 2.39M | 2.32M | 2.29M | 423.19K | 21.35M | 21.35M | 21.35M | 21.35M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $47.28M | $117.66M | $229.97M | $73.70M | $16.05M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $47.28M | $117.66M | $229.97M | $73.70M | $16.05M |
| Net Receivables | $1.23M | $2.21M | $16.11M | $11.50M | $8.99M |
| Inventory | $17.64M | $6.42M | $3.08M | $842.00K | $616.00K |
| Other Current Assets | $1.47M | $2.00M | $9.01M | $3.00M | $431.00K |
| Total Current Assets | $67.63M | $128.29M | $258.18M | $89.05M | $26.09M |
| Property Plant Equipment Net | $15.02M | $9.91M | $8.61M | $7.27M | $5.73M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $8.00K | $23.00K | $- | $- |
| Goodwill and Intangible Assets | $-1.33M | $8.00K | $23.00K | $43.00K | $38.00K |
| Long Term Investments | $1.33M | $-377.00K | $- | $- | $- |
| Tax Assets | $533.00K | $377.00K | $- | $- | $- |
| Other Non-Current Assets | $3.46M | $2.92M | $1.80M | $1.03M | $275.00K |
| Total Non-Current Assets | $19.01M | $12.83M | $10.44M | $8.34M | $6.04M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $86.64M | $141.12M | $268.61M | $97.39M | $32.13M |
| Account Payables | $10.06M | $5.19M | $8.09M | $5.82M | $1.62M |
| Short Term Debt | $2.66M | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $18.25M | $15.50M | $10.72M | $6.62M | $7.54M |
| Total Current Liabilities | $30.97M | $20.68M | $18.81M | $12.43M | $9.16M |
| Long Term Debt | $3.26M | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $3.26M | $- | $- | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $34.23M | $20.68M | $18.81M | $12.43M | $9.16M |
| Preferred Stock | $- | $137.00K | $155.00K | $1.00K | $1.00K |
| Common Stock | $137.00K | $137.00K | $155.00K | $- | $- |
| Retained Earnings | $-445.35M | $-356.38M | $-215.99M | $-119.67M | $-65.76M |
| Accumulated Other Comprehensive Income Loss | $-3.15M | $9.47M | $9.34M | $-3.00M | $-2.85M |
| Other Total Stockholders Equity | $500.78M | $467.08M | $456.14M | $207.62M | $91.57M |
| Total Stockholders Equity | $52.41M | $120.44M | $249.80M | $84.96M | $22.97M |
| Total Equity | $52.41M | $120.44M | $249.80M | $84.96M | $22.97M |
| Total Liabilities and Stockholders Equity | $86.64M | $141.12M | $268.61M | $97.39M | $32.13M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $86.64M | $141.12M | $268.61M | $97.39M | $32.13M |
| Total Investments | $1.33M | $-377.00K | $- | $- | $- |
| Total Debt | $5.92M | $- | $- | $- | $- |
| Net Debt | $-41.35M | $-117.66M | $-229.97M | $-73.70M | $-16.05M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $29.45M | $38.80M | $55.41M | $47.28M | $65.85M | $90.00M | $113.10M | $117.66M | $136.38M | $164.68M | $195.76M | $229.97M | $106.61M | $73.70M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $29.45M | $38.80M | $55.41M | $47.28M | $65.85M | $90.00M | $113.10M | $117.66M | $136.38M | $164.68M | $195.76M | $229.97M | $106.61M | $73.70M |
| Net Receivables | $2.82M | $3.12M | $1.53M | $1.23M | $2.96M | $2.66M | $2.53M | $2.21M | $17.32M | $17.33M | $16.74M | $16.11M | $17.03M | $11.50M |
| Inventory | $768.00K | $1.06M | $3.77M | $17.64M | $4.04M | $2.14M | $4.00M | $6.42M | $1.79M | $1.56M | $1.60M | $3.08M | $1.93M | $842.00K |
| Other Current Assets | $953.00K | $2.84M | $3.15M | $1.47M | $1.25M | $1.31M | $2.73M | $2.00M | $3.05M | $4.73M | $9.38M | $9.01M | $4.31M | $3.00M |
| Total Current Assets | $34.00M | $45.81M | $63.87M | $67.63M | $74.10M | $96.11M | $122.35M | $128.29M | $158.54M | $188.30M | $223.48M | $258.18M | $129.88M | $89.05M |
| Property Plant Equipment Net | $12.55M | $14.08M | $14.78M | $15.02M | $22.49M | $62.28M | $69.69M | $9.91M | $10.14M | $10.05M | $10.09M | $8.61M | $6.75M | $7.27M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $6.00K | $8.00K | $- | $- | $16.00K | $23.00K | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $-1.33M | $3.00K | $4.00K | $6.00K | $8.00K | $10.00K | $11.00K | $16.00K | $23.00K | $32.00K | $43.00K |
| Long Term Investments | $- | $- | $- | $1.33M | $1.21M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $523.00K | $542.00K | $533.00K | $533.00K | $377.00K | $377.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.15M | $2.22M | $2.18M | $3.46M | $1.89M | $3.36M | $4.13M | $2.92M | $2.08M | $2.69M | $1.66M | $1.80M | $3.79M | $1.03M |
| Total Non-Current Assets | $15.22M | $16.84M | $17.50M | $19.01M | $25.97M | $66.02M | $73.82M | $12.83M | $12.23M | $12.75M | $11.76M | $10.44M | $10.58M | $8.34M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $49.22M | $62.65M | $81.37M | $86.64M | $100.08M | $162.13M | $196.17M | $141.12M | $170.77M | $201.05M | $235.25M | $268.61M | $140.46M | $97.39M |
| Account Payables | $7.78M | $6.88M | $12.45M | $10.06M | $9.96M | $7.88M | $9.14M | $5.19M | $5.67M | $4.55M | $5.53M | $8.09M | $12.86M | $5.82M |
| Short Term Debt | $2.29M | $2.84M | $2.75M | $2.66M | $2.88M | $11.00M | $7.41M | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $7.13M | $8.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $283.00K | $85.00K | $7.54M | $18.25M | $9.58M | $7.22M | $8.84M | $15.50M | $12.30M | $10.87M | $10.29M | $10.72M | $8.62M | $6.62M |
| Total Current Liabilities | $17.48M | $18.68M | $22.74M | $30.97M | $22.42M | $26.10M | $25.39M | $20.68M | $17.97M | $15.42M | $15.82M | $18.81M | $21.48M | $12.43M |
| Long Term Debt | $1.70M | $1.96M | $2.64M | $3.26M | $9.08M | $46.41M | $52.22M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $1.70M | $1.96M | $2.64M | $3.26M | $9.08M | $46.41M | $52.22M | $- | $- | $- | $- | $- | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $19.18M | $20.64M | $25.38M | $34.23M | $31.49M | $72.50M | $77.61M | $20.68M | $17.97M | $15.42M | $15.82M | $18.81M | $21.48M | $12.43M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $137.00K | $137.00K | $137.00K | $137.00K | $137.00K | $- | $1.00K | $1.00K |
| Common Stock | $137.00K | $137.00K | $137.00K | $137.00K | $137.00K | $- | $- | $-9.61M | $- | $- | $- | $- | $153.00K | $- |
| Retained Earnings | $-472.29M | $-460.20M | $-444.19M | $-445.35M | $-422.35M | $-407.46M | $-383.11M | $-356.38M | $-321.68M | $-290.81M | $-250.94M | $-215.99M | $-152.93M | $-119.67M |
| Accumulated Other Comprehensive Income Loss | $-1.57M | $-784.00K | $-1.72M | $-3.15M | $-8.85M | $-1.50M | $6.74M | $9.47M | $9.06M | $14.20M | $11.37M | $9.34M | $-7.17M | $-3.00M |
| Other Total Stockholders Equity | $503.76M | $502.86M | $501.75M | $500.78M | $499.65M | $498.59M | $494.80M | $476.82M | $465.29M | $462.10M | $458.86M | $456.45M | $278.92M | $207.62M |
| Total Stockholders Equity | $30.04M | $42.02M | $55.99M | $52.41M | $68.58M | $89.63M | $118.56M | $120.44M | $152.80M | $185.63M | $219.43M | $249.80M | $118.98M | $84.96M |
| Total Equity | $30.04M | $42.02M | $55.99M | $52.41M | $68.58M | $89.63M | $118.56M | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $49.22M | $62.65M | $81.37M | $86.64M | $100.08M | $162.13M | $196.17M | $141.12M | $170.77M | $201.05M | $235.25M | $268.61M | $140.46M | $97.39M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $49.22M | $62.65M | $81.37M | $86.64M | $100.08M | $162.13M | $196.17M | $141.12M | $170.77M | $201.05M | $235.25M | $268.61M | $140.46M | $97.39M |
| Total Investments | $- | $- | $- | $1.33M | $1.21M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $3.99M | $4.80M | $5.39M | $5.92M | $11.96M | $57.41M | $59.63M | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-25.46M | $-34.00M | $-50.03M | $-41.35M | $-53.89M | $-32.59M | $-53.47M | $-117.66M | $-136.38M | $-164.68M | $-195.76M | $-229.97M | $-106.61M | $-73.70M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-88.97M | $-140.39M | $-96.32M | $-53.91M | $-33.28M |
| Depreciation and Amortization | $1.74M | $2.39M | $1.91M | $1.54M | $970.00K |
| Deferred Income Tax | $-156.00K | $-171.00K | $-158.00K | $-4.56M | $- |
| Stock Based Compensation | $5.08M | $10.72M | $6.20M | $1.46M | $114.00K |
| Change in Working Capital | $9.07M | $19.74M | $-6.68M | $-1.41M | $6.43M |
| Accounts Receivables | $- | $98.00K | $-91.00K | $- | $54.00K |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $5.45M | $-2.89M | $1.54M | $4.13M | $7.53M |
| Other Working Capital | $3.62M | $22.54M | $-8.13M | $-5.55M | $-1.16M |
| Other Non Cash Items | $-4.98M | $148.00K | $76.00K | $4.56M | $- |
| Net Cash Provided by Operating Activities | $-78.22M | $-107.56M | $-94.97M | $-52.32M | $-25.77M |
| Investments in Property Plant and Equipment | $-7.01M | $-4.27M | $-2.51M | $-3.02M | $-3.75M |
| Acquisitions Net | $- | $- | $126.98K | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-980 | $- | $- |
| Net Cash Used for Investing Activities | $-7.01M | $-4.27M | $-2.39M | $-3.02M | $-3.75M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $27.33M | $178.98K | $161.76M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $27.52M | $-984.00K | $242.62M | $114.59M | $38.13M |
| Net Cash Used Provided by Financing Activities | $27.52M | $-984.00K | $242.62M | $114.59M | $38.13M |
| Effect of Forex Changes on Cash | $-12.44M | $302.00K | $11.74M | $-1.01M | $-812.00K |
| Net Change in Cash | $-70.46M | $-112.51M | $157.00M | $58.23M | $7.80M |
| Cash at End of Period | $48.61M | $119.06M | $231.58M | $74.57M | $16.34M |
| Cash at Beginning of Period | $119.06M | $231.58M | $74.57M | $16.34M | $8.54M |
| Operating Cash Flow | $-78.22M | $-107.56M | $-94.97M | $-52.32M | $-25.77M |
| Capital Expenditure | $-7.01M | $-4.27M | $-2.51M | $-3.02M | $-3.75M |
| Free Cash Flow | $-85.24M | $-111.83M | $-97.48M | $-55.34M | $-29.52M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | June 30, 2019 | March 31, 2019 | June 30, 2018 | March 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-12.09M | $-16.01M | $1.17M | $-23.00M | $-14.89M | $-24.35M | $-26.73M | $-34.70M | $-30.88M | $-39.87M | $-34.95M | $-38.08M | $-24.98M | $-16.56M | $-16.70M | $-13.48M | $-13.48M | $-8.32M | $-8.32M |
| Depreciation and Amortization | $386.00K | $433.00K | $320.00K | $315.00K | $406.00K | $479.00K | $541.00K | $611.00K | $588.00K | $618.00K | $573.00K | $585.00K | $466.00K | $367.00K | $495.00K | $385.00K | $385.00K | $242.50K | $242.50K |
| Deferred Income Tax | $- | $- | $- | $-156.00K | $- | $- | $- | $35.00K | $- | $- | $-206.00K | $-158.00K | $- | $-13.04M | $- | $- | $- | $- | $- |
| Stock Based Compensation | $895.00K | $1.07M | $973.00K | $1.04M | $1.20M | $1.46M | $1.38M | $1.85M | $3.18M | $3.14M | $2.55M | $2.37M | $3.26M | $238.00K | $330.00K | $364.75K | $364.75K | $28.50K | $28.50K |
| Change in Working Capital | $2.12M | $-486.00K | $-621.00K | $1.86M | $3.41M | $5.63M | $-1.84M | $14.76M | $4.42M | $2.75M | $-2.19M | $1.97M | $-9.73M | $3.16M | $-2.07M | $-353.00K | $-353.00K | $1.61M | $1.61M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00K | $1.00K | $98.00K | $-91.00K | $- | $- | $- | $- | $- | $13.50K | $13.50K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.11M | $-2.68M | $2.09M | $229.00K | $1.77M | $-751.00K | $4.19M | $-490.00K | $1.35M | $-1.17M | $-2.58M | $1.92M | $-7.89M | $5.99M | $1.53M | $- | $- | $- | $- |
| Other Working Capital | $1.01M | $2.20M | $-2.71M | $1.63M | $1.64M | $6.39M | $-6.03M | $15.25M | $3.08M | $3.92M | $288.00K | $140.00K | $-1.84M | $-2.83M | $-3.60M | $-353.00K | $-353.00K | $1.59M | $1.59M |
| Other Non Cash Items | $15.00K | $-2.29M | $-20.28M | $88.00K | $-5.29M | $155.00K | $71.00K | $146.00K | $-1.00K | $- | $3.00K | $76.00K | $- | $13.04M | $- | $- | $- | $- | $- |
| Net Cash Provided by Operating Activities | $-8.67M | $-17.28M | $-18.44M | $-19.85M | $-15.17M | $-16.62M | $-26.58M | $-17.29M | $-22.68M | $-33.36M | $-34.22M | $-33.24M | $-30.98M | $-12.79M | $-17.95M | $-13.08M | $-13.08M | $-6.44M | $-6.44M |
| Investments in Property Plant and Equipment | $-6.00K | $-256.00K | $-392.00K | $-3.90M | $-2.18M | $-413.00K | $-526.00K | $-636.00K | $-978.00K | $-380.00K | $-2.28M | $-1.73M | $-230.00K | $-275.00K | $-561.00K | $-755.50K | $-755.50K | $-937.25K | $-937.25K |
| Acquisitions Net | $-46.40K | $-4.03K | $24.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $46.40K | $66.03K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $126.00K | $- | $285.00K | $- | $755.50K | $755.50K | $937.25K | $937.25K |
| Net Cash Used for Investing Activities | $-6.00K | $-194.00K | $23.81M | $-3.90M | $-2.18M | $-413.00K | $-526.00K | $-636.00K | $-978.00K | $-380.00K | $-2.28M | $-1.61M | $-230.00K | $10.00K | $-561.00K | $-755.50K | $-755.50K | $-937.25K | $-937.25K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-61 | $32.20K | $- | $-27.33M | $-119.03K | $2.08M | $25.25M | $- | $- | $- | $- | $147.00K | $161.60M | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $78.49K | $84.78K | $- | $88.00K | $-119.03K | $2.17M | $25.25M | $-1.09M | $-837 | $105.00K | $- | $156.00K | $174.60M | $66.68M | $1.18M | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $39.19K | $32.00K | $-91.83K | $88.00K | $-3.00K | $2.19M | $25.25M | $-1.09M | $-1.00K | $105.00K | $- | $156.00K | $174.60M | $66.68M | $1.18M | $- | $- | $- | $- |
| Effect of Forex Changes on Cash | $-666.00K | $822.00K | $1.14M | $5.51M | $-6.88M | $-8.35M | $-2.72M | $266.00K | $-4.68M | $2.57M | $2.14M | $13.99M | $1.49M | $226.00K | $-3.96M | $- | $- | $- | $- |
| Net Change in Cash | $-9.35M | $-16.62M | $6.51M | $-18.45M | $-24.23M | $-23.19M | $-4.58M | $-18.75M | $-28.34M | $-31.06M | $-34.36M | $-20.70M | $144.88M | $54.12M | $-21.29M | $14.56M | $14.56M | $1.95M | $1.95M |
| Cash at End of Period | $29.45M | $38.80M | $55.41M | $48.61M | $67.06M | $91.29M | $114.48M | $119.06M | $137.81M | $166.16M | $197.21M | $231.58M | $252.28M | $107.40M | $53.28M | $18.64M | $18.64M | $4.08M | $4.08M |
| Cash at Beginning of Period | $38.80M | $55.41M | $48.91M | $67.06M | $91.29M | $114.48M | $119.06M | $137.81M | $166.16M | $197.21M | $231.58M | $252.28M | $107.40M | $53.28M | $74.57M | $4.08M | $4.08M | $2.13M | $2.13M |
| Operating Cash Flow | $-8.67M | $-17.28M | $-18.44M | $-19.85M | $-15.17M | $-16.62M | $-26.58M | $-17.29M | $-22.68M | $-33.36M | $-34.22M | $-33.24M | $-30.98M | $-12.79M | $-17.95M | $-13.08M | $-13.08M | $-6.44M | $-6.44M |
| Capital Expenditure | $-6.00K | $-256.00K | $-392.00K | $-3.90M | $-2.18M | $-413.00K | $-526.00K | $-636.00K | $-978.00K | $-380.00K | $-2.28M | $-1.73M | $-230.00K | $-275.00K | $-561.00K | $-755.50K | $-755.50K | $-937.25K | $-937.25K |
| Free Cash Flow | $-8.68M | $-17.53M | $-18.83M | $-23.75M | $-17.35M | $-17.03M | $-27.11M | $-17.93M | $-23.66M | $-33.74M | $-36.50M | $-34.97M | $-31.21M | $-13.06M | $-18.52M | $-13.84M | $-13.84M | $-7.38M | $-7.38M |
Freeline Therapeutics Holdings plc Dividends
Explore Freeline Therapeutics Holdings plc's dividend history, including dividend yield, payout ratio, and historical payments.
Freeline Therapeutics Holdings plc News
Read the latest news about Freeline Therapeutics Holdings plc, including recent articles, headlines, and updates.
Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Acquisition of Freeline by Syncona Becomes Effective
LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that, in connection with Syncona's acquisition of Freeline by way of a scheme of arrangement (the “Scheme”), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the “Scheme Circular”) has been delivered to the Registrar of Companies. Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited.
Freeline Shareholders Approve Acquisition by Syncona
LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited (“Syncona Portfolio”), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share (“ADS”) in cash (the “Acquisition”). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 (the “Scheme”).
FREELINE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Freeline Therapeutics Holdings plc (NasdaqCM: FRLN) to Syncona Ltd. Under the terms of the proposed transaction, shareholders of Freeline will receive $6.50 for each American Depositary Share (ADS) of Freeline that they own. KSF is seeking to determine whether this consideration and the process that led to it.
FRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Freeline Therapeutics Holdings plc (NASDAQ: FRLN) to Syncona Ltd. for $6.50 per American Depositary Share is fair to Freeline shareholders. Halper Sadeh encourages Freeline shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concer.
Syncona to Acquire Freeline Therapeutics
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona's initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline's independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline's near-term capital needs and support ongoing advancement of its programs LONDON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has entered into a definitive agreement with a newly established portfolio company of Syncona Ltd (LON: SYNC), a leading life science investor focused on creating, building and scaling global leaders in life science, to acquire Freeline in an all-cash transaction. Under the agreement, the newly established portfolio company will acquire all shares of Freeline not currently owned by Syncona for $6.50 per American Depositary Share (ADS).
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Con
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate, in patients with Gaucher disease Type 1 at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress being held October 24-27, 2023 in Brussels, Belgium. The oral presentation will include data on safety, tolerability, GCase enzyme activity, substrate, and hemoglobin and platelet levels from the first two patients treated with FLT201.
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update.
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated virus (AAV) gene therapy candidate in Gaucher disease Type 1, on Tuesday, August 1, 2023 at 8:30 a.m. ET. The event will feature Gaucher disease expert, Dr. Reena Sharma, Consultant Adult Metabolic Medicine and Honorary Senior Lecturer at the Salford Royal Hospital in the United Kingdom, who will discuss the epidemiology, treatment landscape, and unmet need in Gaucher disease.
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Freeline to Present at 2023 Jefferies Healthcare Conference
LONDON, June 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 2023 Jefferies Healthcare Conference being held in New York on June 7-9, 2023.
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
LONDON, April 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 22nd Annual Needham Virtual Healthcare Conference being held on April 17-20, 2023.
Freeline to Present at the Stifel Healthcare Conference
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg.
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congress to be held in London, July 9-13, 2022.
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
Five abstracts accepted with new research and technology insights and data to further enhance AAV-based gene therapy candidates Five abstracts accepted with new research and technology insights and data to further enhance AAV-based gene therapy candidates
Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster presentations at the 18th Annual WORLDSymposium™, a research conference dedicated to lysosomal storage diseases, taking place February 7 – 11, 2022 in San Diego, California. The presentations will include updated data from the Company's ongoing Phase 1/2 MARVEL-1 clinical trial evaluating FLT190 for the treatment of patients with Fabry disease and the clinical trial design for GALILEO-1, a Phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1.
Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) gave an update on its investigational Fabry disease treatment FLT190, currently in a Phase 1/2 trial, saying the candidate proved durable in the second patient tested. Fabry disease is an inherited metabolic disorder resulting from the absent or markedly deficient activity of lysosomal enzyme α-galactosidase A, or α-Gal A.
Freeline Therapeutics to Present FLT180a Data at the 2021 ASH Annual Meeting
LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that data from its long-term follow-up study to its Phase 1/2 B-AMAZE clinical trial of FLT180a for the treatment of hemophilia B will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, being held in Atlanta, Georgia and virtually on Saturday, December 11 through Tuesday, December 14, 2021.
Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Financial Results on Monday, August 16
Guidance across all programs remains unchanged for expected data and clinical development milestones in 2021 Guidance across all programs remains unchanged for expected data and clinical development milestones in 2021
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for FRLN.